Research ArticleDrug Development

The druggable genome and support for target identification and validation in drug development

See allHide authors and affiliations

Science Translational Medicine  29 Mar 2017:
Vol. 9, Issue 383, eaag1166
DOI: 10.1126/scitranslmed.aag1166

Article Information

vol. 9 no. 383

Print ISSN: 
Online ISSN: 
  • Received for publication July 25, 2016
  • Accepted for publication January 27, 2017

Author Information

  1. Chris Finan1,2,*,
  2. Anna Gaulton3,*,
  3. Felix A. Kruger1,4,
  4. R. Thomas Lumbers1,2,
  5. Tina Shah1,2,
  6. Jorgen Engmann1,2,
  7. Luana Galver5,
  8. Ryan Kelley5,
  9. Anneli Karlsson3,
  10. Rita Santos3,,
  11. John P. Overington3,4,,
  12. Aroon D. Hingorani1,2,*, and
  13. Juan P. Casas2,*,
  1. 1Institute of Cardiovascular Science, Faculty of Population Health, University College London, London WC1E 6BT, U.K.
  2. 2Farr Institute of Health Informatics, University College London, London WC1E 6BT, U.K.
  3. 3European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SD, U.K.
  4. 4BenevolentAI, 40 Churchway, London, U.K.
  5. 5Illumina Inc., 5200 Illumina Way, San Diego, CA 92122, USA.
  1. Corresponding author. Email: jpo{at} (J.P.O.); a.hingorani{at} (A.D.H.); jp.casas{at} (J.P.C.)
    • * These authors contributed equally to this work.

    • Present address: GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, U.K.


    Article usage

    Mar 20176299597954
    Apr 20174276474714
    May 2017737165178
    Jun 201765997124
    Jul 2017675120123
    Aug 2017644114112
    Sep 20172996568